Indices of iron homeostasis in asymptomatic subjects with HFE mutations and moderate ferritin elevation during iron removal treatment
We analysed iron biomarkers and their relationships in 30 subjects with HFE mutations and moderate hyperferritinaemia undergoing iron removal at our blood donation centre. Body mass index (BMI) and liver enzymes were assessed. Serum iron (SI), ferritin, transferrin saturation (TSAT), hepcidin and no...
Saved in:
| Published in | Blood cells, molecules, & diseases Vol. 97; p. 102689 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
01.11.2022
|
| Online Access | Get full text |
Cover
Loading…
| Abstract | We analysed iron biomarkers and their relationships in 30 subjects with HFE mutations and moderate hyperferritinaemia undergoing iron removal at our blood donation centre. Body mass index (BMI) and liver enzymes were assessed. Serum iron (SI), ferritin, transferrin saturation (TSAT), hepcidin and non-transferrin bound iron (NTBI) were measured serially. Seventeen subjects had p.C282Y/p.C282Y, nine p.C282Y/p.H63D, four p.H63D/p.H63D. Median age (p = 0.582), BMI (p = 0.500) and ferritin (p = 0.089) were comparable. At baseline, 12/17 p.C282Y/p.C282Y and 2/9 p.C282Y/p.H63D had measurable NTBI (p = 0.003). The p.C282Y/p.C282Y had higher TSAT (p < 0.001), lower hepcidin (p = 0.031) and hepcidin/ferritin ratio (p = 0.073). After treatment, iron indices were similar among groups, except TSAT (higher in p.C282Y/p.C282Y; p = 0.06). Strong relationships were observed between ferritin and TSAT (R = 0.71), NTBI and TSAT (R = 0.61), NTBI and SI (R = 0.54) in p.C282Y/p.C282Y. Hepcidin correlated weakly with ferritin in p.C282Y/p.C282Y (R = 0.37) but strongly in p.C282Y/p.H63D (R = 0.66) and p.H63D/p.H63D (R = 0.72), while relationships with TSAT were weak (R = 0.27), moderate (R = 0.55) and strong (R = 0.61), respectively. Low penetrance p.C282Y/p.C282Y phenotype displays hepcidin dysregulation and biochemical risk for iron toxicity.We analysed iron biomarkers and their relationships in 30 subjects with HFE mutations and moderate hyperferritinaemia undergoing iron removal at our blood donation centre. Body mass index (BMI) and liver enzymes were assessed. Serum iron (SI), ferritin, transferrin saturation (TSAT), hepcidin and non-transferrin bound iron (NTBI) were measured serially. Seventeen subjects had p.C282Y/p.C282Y, nine p.C282Y/p.H63D, four p.H63D/p.H63D. Median age (p = 0.582), BMI (p = 0.500) and ferritin (p = 0.089) were comparable. At baseline, 12/17 p.C282Y/p.C282Y and 2/9 p.C282Y/p.H63D had measurable NTBI (p = 0.003). The p.C282Y/p.C282Y had higher TSAT (p < 0.001), lower hepcidin (p = 0.031) and hepcidin/ferritin ratio (p = 0.073). After treatment, iron indices were similar among groups, except TSAT (higher in p.C282Y/p.C282Y; p = 0.06). Strong relationships were observed between ferritin and TSAT (R = 0.71), NTBI and TSAT (R = 0.61), NTBI and SI (R = 0.54) in p.C282Y/p.C282Y. Hepcidin correlated weakly with ferritin in p.C282Y/p.C282Y (R = 0.37) but strongly in p.C282Y/p.H63D (R = 0.66) and p.H63D/p.H63D (R = 0.72), while relationships with TSAT were weak (R = 0.27), moderate (R = 0.55) and strong (R = 0.61), respectively. Low penetrance p.C282Y/p.C282Y phenotype displays hepcidin dysregulation and biochemical risk for iron toxicity. |
|---|---|
| AbstractList | We analysed iron biomarkers and their relationships in 30 subjects with HFE mutations and moderate hyperferritinaemia undergoing iron removal at our blood donation centre. Body mass index (BMI) and liver enzymes were assessed. Serum iron (SI), ferritin, transferrin saturation (TSAT), hepcidin and non-transferrin bound iron (NTBI) were measured serially. Seventeen subjects had p.C282Y/p.C282Y, nine p.C282Y/p.H63D, four p.H63D/p.H63D. Median age (p = 0.582), BMI (p = 0.500) and ferritin (p = 0.089) were comparable. At baseline, 12/17 p.C282Y/p.C282Y and 2/9 p.C282Y/p.H63D had measurable NTBI (p = 0.003). The p.C282Y/p.C282Y had higher TSAT (p < 0.001), lower hepcidin (p = 0.031) and hepcidin/ferritin ratio (p = 0.073). After treatment, iron indices were similar among groups, except TSAT (higher in p.C282Y/p.C282Y; p = 0.06). Strong relationships were observed between ferritin and TSAT (R = 0.71), NTBI and TSAT (R = 0.61), NTBI and SI (R = 0.54) in p.C282Y/p.C282Y. Hepcidin correlated weakly with ferritin in p.C282Y/p.C282Y (R = 0.37) but strongly in p.C282Y/p.H63D (R = 0.66) and p.H63D/p.H63D (R = 0.72), while relationships with TSAT were weak (R = 0.27), moderate (R = 0.55) and strong (R = 0.61), respectively. Low penetrance p.C282Y/p.C282Y phenotype displays hepcidin dysregulation and biochemical risk for iron toxicity.We analysed iron biomarkers and their relationships in 30 subjects with HFE mutations and moderate hyperferritinaemia undergoing iron removal at our blood donation centre. Body mass index (BMI) and liver enzymes were assessed. Serum iron (SI), ferritin, transferrin saturation (TSAT), hepcidin and non-transferrin bound iron (NTBI) were measured serially. Seventeen subjects had p.C282Y/p.C282Y, nine p.C282Y/p.H63D, four p.H63D/p.H63D. Median age (p = 0.582), BMI (p = 0.500) and ferritin (p = 0.089) were comparable. At baseline, 12/17 p.C282Y/p.C282Y and 2/9 p.C282Y/p.H63D had measurable NTBI (p = 0.003). The p.C282Y/p.C282Y had higher TSAT (p < 0.001), lower hepcidin (p = 0.031) and hepcidin/ferritin ratio (p = 0.073). After treatment, iron indices were similar among groups, except TSAT (higher in p.C282Y/p.C282Y; p = 0.06). Strong relationships were observed between ferritin and TSAT (R = 0.71), NTBI and TSAT (R = 0.61), NTBI and SI (R = 0.54) in p.C282Y/p.C282Y. Hepcidin correlated weakly with ferritin in p.C282Y/p.C282Y (R = 0.37) but strongly in p.C282Y/p.H63D (R = 0.66) and p.H63D/p.H63D (R = 0.72), while relationships with TSAT were weak (R = 0.27), moderate (R = 0.55) and strong (R = 0.61), respectively. Low penetrance p.C282Y/p.C282Y phenotype displays hepcidin dysregulation and biochemical risk for iron toxicity. |
| ArticleNumber | 102689 |
| Author | Pehlic, Vildana Passweg, Jakob Moe, Morten K. Cattaneo, Marco Leitner, Gerda Infanti, Laura Benkert, Pascal Worel, Nina Buser, Andreas Holbro, Andreas |
| Author_xml | – sequence: 1 givenname: Laura surname: Infanti fullname: Infanti, Laura – sequence: 2 givenname: Gerda surname: Leitner fullname: Leitner, Gerda – sequence: 3 givenname: Morten K. surname: Moe fullname: Moe, Morten K. – sequence: 4 givenname: Vildana surname: Pehlic fullname: Pehlic, Vildana – sequence: 5 givenname: Pascal surname: Benkert fullname: Benkert, Pascal – sequence: 6 givenname: Marco surname: Cattaneo fullname: Cattaneo, Marco – sequence: 7 givenname: Andreas surname: Holbro fullname: Holbro, Andreas – sequence: 8 givenname: Jakob surname: Passweg fullname: Passweg, Jakob – sequence: 9 givenname: Nina surname: Worel fullname: Worel, Nina – sequence: 10 givenname: Andreas surname: Buser fullname: Buser, Andreas |
| BookMark | eNp9kMFOwzAMhiMEEmPwApxy5NKRpF3bHBEabBISFzhHaeKwTE0yknSIB-C96SgnDhwsW_b_2_J3gU598IDQNSULSmh9u1t0yukFI4yNDVa3_ATNKOF1MQY9PdYNL3jD63N0kdKOEEIpb2foa-O1VZBwMNjG4PE2OAgpy2QTth7L9On2OTiZrcJp6HagcsIfNm_x-mGF3ZDHSfAJS6-xCxqizIANxGjzaIceDj8CrIdo_dt0I4ILB9njHEFmBz5fojMj-wRXv3mOXh9WL_fr4un5cXN_91SoklW5UEq3jW7ANGy5bFvOwRjZ6LJriAJTMqJ0VzJNeMkMXValqk1b0poYWhvVSVXO0c20dx_D-wApC2eTgr6XHsKQxAhuSSpSsWqUtpNUxZBSBCOUnX7NUdpeUCKO5MVOHMmLI3kxkR-t7I91H62T8fM_0zeirI6o |
| CitedBy_id | crossref_primary_10_1159_000536657 crossref_primary_10_3389_fmed_2024_1362941 |
| Cites_doi | 10.1182/blood-2010-01-261875 10.1016/j.bbamcr.2012.01.014 10.1016/S0140-6736(03)12602-5 10.1373/clinchem.2006.068684 10.1089/10906570050114902 10.1002/jca.21451 10.1002/hep.22972 10.1016/j.cca.2011.12.015 10.1016/S2352-3026(17)30214-4 10.1056/NEJMoa073286 10.1373/clinchem.2009.140053 10.1136/gut.51.5.723 10.1182/blood-2003-03-0807 10.1016/j.ab.2005.03.008 10.3324/haematol.2010.033449 10.1097/MCG.0b013e3181919a33 10.1111/ijlh.12347 10.1053/gast.1996.v110.pm8613000 10.1111/j.1365-2141.2008.07273.x 10.1016/j.jhep.2010.03.001 10.14309/ajg.0000000000000315 10.1016/S0168-8278(00)80240-8 10.1182/blood-2007-06-096503 10.1007/s12072-018-9855-0 10.5604/01.3001.0012.3169 10.1182/blood.2021011338 10.1016/j.cgh.2006.07.009 10.1016/j.bbagen.2011.07.014 10.1159/000363490 10.1182/blood.V72.4.1416.1416 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION 7X8 |
| DOI | 10.1016/j.bcmd.2022.102689 |
| DatabaseName | CrossRef MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1096-0961 |
| ExternalDocumentID | 10_1016_j_bcmd_2022_102689 |
| GroupedDBID | --- --K --M .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 23N 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ AAAJQ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AATTM AAXKI AAXUO AAYWO AAYXX ABBQC ABFNM ABFRF ABGSF ABJNI ABLJU ABMAC ABMZM ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFGL ADMUD ADNMO ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AFJKZ AFPUW AFTJW AFXIZ AGCQF AGEKW AGHFR AGQPQ AGRDE AGRNS AGUBO AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CITATION CJTIS COF CS3 DM4 DU5 EBS EFBJH EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM LG5 LUGTX M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. PQQKQ Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SSH SSI SSU SSZ T5K UNMZH X7M XPP ZMT ~G- 7X8 |
| ID | FETCH-LOGICAL-c324t-ccd87d7ef72558899effa7d3b70cef320cdb32d0932f1543c6f83160f16fcbac3 |
| ISSN | 1079-9796 1096-0961 |
| IngestDate | Thu Jul 10 22:42:42 EDT 2025 Thu Apr 24 23:05:43 EDT 2025 Tue Jul 01 02:24:39 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c324t-ccd87d7ef72558899effa7d3b70cef320cdb32d0932f1543c6f83160f16fcbac3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doi.org/10.1016/j.bcmd.2022.102689 |
| PQID | 2685040424 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2685040424 crossref_citationtrail_10_1016_j_bcmd_2022_102689 crossref_primary_10_1016_j_bcmd_2022_102689 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-11-00 20221101 |
| PublicationDateYYYYMMDD | 2022-11-01 |
| PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-00 |
| PublicationDecade | 2020 |
| PublicationTitle | Blood cells, molecules, & diseases |
| PublicationYear | 2022 |
| References | Niederau (10.1016/j.bcmd.2022.102689_bb0035) 1996; 110 Adams (10.1016/j.bcmd.2022.102689_bb0130) 2018; 12 Kowdley (10.1016/j.bcmd.2022.102689_bb0110) 2019; 114 Brissot (10.1016/j.bcmd.2022.102689_bb0055) 2012; 1820 Swinkels (10.1016/j.bcmd.2022.102689_bb0060) 2006; 52 Girelli (10.1016/j.bcmd.2022.102689_bb0120) 2011; 96 Merryweather-Clarke (10.1016/j.bcmd.2022.102689_bb0010) 2000; 4 Allen (10.1016/j.bcmd.2022.102689_bb0080) 2008; 358 Adams (10.1016/j.bcmd.2022.102689_bb0135) 2010; 116 Holmstrom (10.1016/j.bcmd.2022.102689_bb0020) 2002; 51 Ong (10.1016/j.bcmd.2022.102689_bb0140) 2017; 4 Itkonen (10.1016/j.bcmd.2022.102689_bb0115) 2012; 413 Esposito (10.1016/j.bcmd.2022.102689_bb0050) 2003; 102 Piperno (10.1016/j.bcmd.2022.102689_bb0065) 2007; 110 Adams (10.1016/j.bcmd.2022.102689_bb0015) 2015; 37 Walsh (10.1016/j.bcmd.2022.102689_bb0095) 2006; 4 Girelli (10.1016/j.bcmd.2022.102689_bb0005) 2022; 139 Gurrin (10.1016/j.bcmd.2022.102689_bb0090) 2009; 50 Ganz (10.1016/j.bcmd.2022.102689_bb0025) 2012; 1823 (10.1016/j.bcmd.2022.102689_bb0105) 2010; 53 Barton (10.1016/j.bcmd.2022.102689_bb0075) 2018; 17 Cheng (10.1016/j.bcmd.2022.102689_bb0070) 2009; 43 Pilling (10.1016/j.bcmd.2022.102689_bb0085) 2019; 364 Jacobs (10.1016/j.bcmd.2022.102689_bb0150) 2005; 341 Kroot (10.1016/j.bcmd.2022.102689_bb0030) 2011; 57 van Dijk (10.1016/j.bcmd.2022.102689_bb0045) 2008; 142 Loreal (10.1016/j.bcmd.2022.102689_bb0155) 2000; 32 Rombout-Sestrienkova (10.1016/j.bcmd.2022.102689_bb0125) 2016; 31 Bridle (10.1016/j.bcmd.2022.102689_bb0040) 2003; 361 Aruoma (10.1016/j.bcmd.2022.102689_bb0145) 1988; 72 Ryan (10.1016/j.bcmd.2022.102689_bb0100) 2015; 133 |
| References_xml | – volume: 116 start-page: 317 issue: 3 year: 2010 ident: 10.1016/j.bcmd.2022.102689_bb0135 article-title: How I treat hemochromatosis publication-title: Blood doi: 10.1182/blood-2010-01-261875 – volume: 1823 start-page: 1434 issue: 9 year: 2012 ident: 10.1016/j.bcmd.2022.102689_bb0025 article-title: Hepcidin and iron homeostasis publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbamcr.2012.01.014 – volume: 361 start-page: 669 issue: 9358 year: 2003 ident: 10.1016/j.bcmd.2022.102689_bb0040 article-title: Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis publication-title: Lancet doi: 10.1016/S0140-6736(03)12602-5 – volume: 52 start-page: 950 issue: 6 year: 2006 ident: 10.1016/j.bcmd.2022.102689_bb0060 article-title: Hereditary hemochromatosis: genetic complexity and new diagnostic approaches publication-title: Clin. Chem. doi: 10.1373/clinchem.2006.068684 – volume: 4 start-page: 183 issue: 2 year: 2000 ident: 10.1016/j.bcmd.2022.102689_bb0010 article-title: Geography of HFE C282Y and H63D mutations publication-title: Genet. Test. doi: 10.1089/10906570050114902 – volume: 31 start-page: 564 issue: 6 year: 2016 ident: 10.1016/j.bcmd.2022.102689_bb0125 article-title: Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy publication-title: J. Clin. Apher. doi: 10.1002/jca.21451 – volume: 50 start-page: 94 issue: 1 year: 2009 ident: 10.1016/j.bcmd.2022.102689_bb0090 article-title: HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity publication-title: Hepatology doi: 10.1002/hep.22972 – volume: 413 start-page: 696 issue: 7–8 year: 2012 ident: 10.1016/j.bcmd.2022.102689_bb0115 article-title: Preanalytical factors and reference intervals for serum hepcidin LC-MS/MS method publication-title: Clin. Chim. Acta doi: 10.1016/j.cca.2011.12.015 – volume: 4 start-page: e607 issue: 12 year: 2017 ident: 10.1016/j.bcmd.2022.102689_bb0140 article-title: Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-iron): a multicentre, participant-blinded, randomised controlled trial publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(17)30214-4 – volume: 358 start-page: 221 issue: 3 year: 2008 ident: 10.1016/j.bcmd.2022.102689_bb0080 article-title: Iron-overload-related disease in HFE hereditary hemochromatosis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa073286 – volume: 57 start-page: 1650 issue: 12 year: 2011 ident: 10.1016/j.bcmd.2022.102689_bb0030 article-title: Hepcidin in human iron disorders: diagnostic implications publication-title: Clin. Chem. doi: 10.1373/clinchem.2009.140053 – volume: 51 start-page: 723 issue: 5 year: 2002 ident: 10.1016/j.bcmd.2022.102689_bb0020 article-title: Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls publication-title: Gut doi: 10.1136/gut.51.5.723 – volume: 102 start-page: 2670 issue: 7 year: 2003 ident: 10.1016/j.bcmd.2022.102689_bb0050 article-title: Labile plasma iron in iron overload: redox activity and susceptibility to chelation publication-title: Blood doi: 10.1182/blood-2003-03-0807 – volume: 341 start-page: 241 issue: 2 year: 2005 ident: 10.1016/j.bcmd.2022.102689_bb0150 article-title: Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform publication-title: Anal. Biochem. doi: 10.1016/j.ab.2005.03.008 – volume: 96 start-page: 500 issue: 4 year: 2011 ident: 10.1016/j.bcmd.2022.102689_bb0120 article-title: A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis publication-title: Haematologica doi: 10.3324/haematol.2010.033449 – volume: 43 start-page: 569 issue: 6 year: 2009 ident: 10.1016/j.bcmd.2022.102689_bb0070 article-title: Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes publication-title: J. Clin. Gastroenterol. doi: 10.1097/MCG.0b013e3181919a33 – volume: 37 start-page: 25 year: 2015 ident: 10.1016/j.bcmd.2022.102689_bb0015 article-title: Epidemiology and diagnostic testing for hemochromatosis and iron overload publication-title: Int. J. Lab. Hematol. doi: 10.1111/ijlh.12347 – volume: 110 start-page: 1107 issue: 4 year: 1996 ident: 10.1016/j.bcmd.2022.102689_bb0035 article-title: Long-term survival in patients with hereditary hemochromatosis publication-title: Gastroenterology doi: 10.1053/gast.1996.v110.pm8613000 – volume: 364 year: 2019 ident: 10.1016/j.bcmd.2022.102689_bb0085 article-title: Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK biobank publication-title: BMJ – volume: 142 start-page: 979 issue: 6 year: 2008 ident: 10.1016/j.bcmd.2022.102689_bb0045 article-title: Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels publication-title: Br. J. Haematol. doi: 10.1111/j.1365-2141.2008.07273.x – volume: 53 start-page: 3 issue: 1 year: 2010 ident: 10.1016/j.bcmd.2022.102689_bb0105 article-title: EASL clinical practice guidelines for HFE hemochromatosis publication-title: J Hepatol doi: 10.1016/j.jhep.2010.03.001 – volume: 114 start-page: 1202 issue: 8 year: 2019 ident: 10.1016/j.bcmd.2022.102689_bb0110 article-title: ACG clinical guideline: hereditary hemochromatosis publication-title: Am. J. Gastroenterol. doi: 10.14309/ajg.0000000000000315 – volume: 32 start-page: 727 issue: 5 year: 2000 ident: 10.1016/j.bcmd.2022.102689_bb0155 article-title: Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method publication-title: J. Hepatol. doi: 10.1016/S0168-8278(00)80240-8 – volume: 110 start-page: 4096 issue: 12 year: 2007 ident: 10.1016/j.bcmd.2022.102689_bb0065 article-title: Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis publication-title: Blood doi: 10.1182/blood-2007-06-096503 – volume: 12 start-page: 83 issue: 2 year: 2018 ident: 10.1016/j.bcmd.2022.102689_bb0130 article-title: Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype publication-title: Hepatol. Int. doi: 10.1007/s12072-018-9855-0 – volume: 17 start-page: 871 issue: 5 year: 2018 ident: 10.1016/j.bcmd.2022.102689_bb0075 article-title: Cirrhosis in hemochromatosis: independent risk factors in 368 HFE p. C282Y homozygotes publication-title: Ann. Hepatol. doi: 10.5604/01.3001.0012.3169 – volume: 139 issue: 20 year: 2022 ident: 10.1016/j.bcmd.2022.102689_bb0005 article-title: Hemochromatosis classification: update and recommendations by the BIOIRON society publication-title: Blood doi: 10.1182/blood.2021011338 – volume: 4 start-page: 1403 issue: 11 year: 2006 ident: 10.1016/j.bcmd.2022.102689_bb0095 article-title: The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis publication-title: Clin. Gastroenterol. Hepatol. doi: 10.1016/j.cgh.2006.07.009 – volume: 1820 start-page: 403 issue: 3 year: 2012 ident: 10.1016/j.bcmd.2022.102689_bb0055 article-title: Non-transferrin bound iron: a key role in iron overload and iron toxicity publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbagen.2011.07.014 – volume: 133 start-page: 155 issue: 2 year: 2015 ident: 10.1016/j.bcmd.2022.102689_bb0100 article-title: Correlates of hepcidin and NTBI according to HFE status in patients referred to a liver centre publication-title: Acta Haematol. doi: 10.1159/000363490 – volume: 72 start-page: 1416 issue: 4 year: 1988 ident: 10.1016/j.bcmd.2022.102689_bb0145 article-title: Nontransferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy publication-title: Blood doi: 10.1182/blood.V72.4.1416.1416 |
| SSID | ssj0001198 |
| Score | 2.3585978 |
| Snippet | We analysed iron biomarkers and their relationships in 30 subjects with HFE mutations and moderate hyperferritinaemia undergoing iron removal at our blood... |
| SourceID | proquest crossref |
| SourceType | Aggregation Database Enrichment Source Index Database |
| StartPage | 102689 |
| Title | Indices of iron homeostasis in asymptomatic subjects with HFE mutations and moderate ferritin elevation during iron removal treatment |
| URI | https://www.proquest.com/docview/2685040424 |
| Volume | 97 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FVEJcELQgykuLhLhYjvyKHR8j1JISwgG10JvlXe-qiWK7Smyk9t7_wU9lZne9ScpDlIsVOc7aynye134zQ8hbHoGNKqR0E-kxN5IydtOcSRf3uKJRmHNPjfOZfY4nZ9HH8-F5r_dji7XUNmzAr39bV_I_UoVzIFeskr2DZO2icAI-g3zhCBKG4z_J-KQq8D1XbR9WIMaLuhQ1uHvYZGReOfn6qrxsat2Udd2yhWJuqMzr5PjIKdvG8OAweY4jcbBthCOxV2ODnUSWQudru1pGdY-VKOvv2wz1nW1hpME7uBmg4FHq2btaEyHGzHaQ9eNPKgmStQXa1kR8EvPGVOJ8EKtN0mCmiYuKIVw508FGsV8s52pW-9f5ssj1RPAumQFxsG-TGVr_eknqpokectspaE3gNRoWHKJYDx36RfnrPMRiwHiJPWCDYLC5eLfT9i0LaHmJHeVtkeEaGa6R6TXukb0AApGgT_bG0y_fptba-36qyy3Ng5vCLM0hvP0ku87Pru1XDs3pI_LQRCJ0rGH1mPREtU8OxlUOiLmi76jiBqtNl31yf2YoGAfkxoCO1pIiIOgW6Oi8otugox3oKIKOAuioBR0F0NEOdLQDHbWgoxp0-h4GdNSC7gk5Oz46fT9xzSwPl4PL3ricF6OkSIRMIIYdQZAvpMyTImSJx4UMA48XLAwKD8IJCV59yGM5Cv3Yk34sOct5-JT0q7oSzwjljPsxG-IwHxZx7Nc2glXZME4KNkyD_JD43Z-ccdPoHuetLLM_i_eQOPY3l7rNy1-vftPJLgNtjG9VXom6XWfw7RDMYhREz--04gvyYPM6vCT9ZtWKV-DtNuy1AdxPAxixLg |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Indices+of+iron+homeostasis+in+asymptomatic+subjects+with+HFE+mutations+and+moderate+ferritin+elevation+during+iron+removal+treatment&rft.jtitle=Blood+cells%2C+molecules%2C+%26+diseases&rft.au=Infanti%2C+Laura&rft.au=Leitner%2C+Gerda&rft.au=Moe%2C+Morten+K.&rft.au=Pehlic%2C+Vildana&rft.date=2022-11-01&rft.issn=1079-9796&rft.volume=97&rft.spage=102689&rft_id=info:doi/10.1016%2Fj.bcmd.2022.102689&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_bcmd_2022_102689 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-9796&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-9796&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-9796&client=summon |